Catella AB
STO:CAT B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Catella AB
STO:CAT B
|
SE |
|
J
|
JSP Industrial Pharmacy (Thailand) PCL
SET:JSP
|
TH |
|
VGP NV
XBRU:VGP
|
BE |
|
eFFECTOR Therapeutics Inc
F:LWK1
|
US |
|
Guoguang Electric Co Ltd Chengdu
SSE:688776
|
CN |
|
A
|
AB&Company Co Ltd
TSE:9251
|
JP |
|
S
|
Sime Darby Plantation Bhd
KLSE:SIMEPLT
|
MY |
|
Daibiru Corp
TSE:8806
|
JP |
|
A
|
Ashok Alco-Chem Ltd
BSE:524594
|
IN |
|
Natural Resource Partners LP
NYSE:NRP
|
US |
|
M
|
M3-Brigade Acquisition V Corp
NASDAQ:MBAV
|
US |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is CAT B's stock price target?
Not Available
CAT B doesn't have any price targets made by Wall Street professionals.
What is Catella AB's Revenue forecast?
Projected CAGR
5%
For the last 9 years the
compound annual growth rate for
Catella AB's revenue is
0%.
The projected
CAGR
for the next 3 years is
5%.
What is Catella AB's Operating Income forecast?
Projected CAGR
4%
For the last 9 years the
compound annual growth rate for
Catella AB's operating income is
3%.
The projected
CAGR
for the next 3 years is
4%.
What is Catella AB's Net Income forecast?
Projected CAGR
67%
For the last 9 years the
compound annual growth rate for
Catella AB's net income is
-18%.
The projected
CAGR
for the next 3 years is
67%.
